Page 83 - 《中国药房》2024年20期
P. 83
管纳入患者未使用负荷剂量的左西孟旦,但其剂量仍偏 and septic shock:sepsis-3[J]. JAMA,2016,315(8):801-810.
高[最新的一项 Meta 分析结果显示,脓毒症患者使用左 [ 9 ] BOISSIER F,AISSAOUI N. Septic cardiomyopathy:diag‐
[20]
西孟旦的最佳剂量应为 0.1 μg/(kg·min) ]。(3)本研究 nosis and management[J]. J Intensive Med,2022,2(1):
为阴性结果,可能与样本量较小有关。 8-16.
[10] HERPAIN A,BOUCHEZ S,GIRARDIS M,et al. Use of
综上所述,对于经充分液体复苏、MAP≥65 mmHg
levosimendan in intensive care unit settings:an opinion
且接受PiCCO监测的感染性休克合并心肌抑制患者,左
paper[J]. J Cardiovasc Pharmacol,2019,73(1):3-14.
西孟旦在改善心脏功能和血流动力学方面的作用与多
[11] RHODES A,EVANS L E,ALHAZZANI W,et al. Survi-
巴酚丁胺相当,且不会影响患者预后,也不会增加低血
ving sepsis campaign:international guidelines for manage‐
压等不良反应的发生风险。鉴于左西孟旦易获得,其治 ment of sepsis and septic shock:2016[J]. Intensive Care
疗成本与多巴酚丁胺大致相当,故临床可考虑选用。本 Med,2017,43(3):304-377.
课题组后续拟开展更大样本量的临床研究以进一步探 [12] 刘红娟,耿静,何志红,等. 左西孟旦治疗脓毒症心肌抑
索左西孟旦在感染性休克合并心肌抑制患者中的临床 制的疗效及对心功能的影响[J]. 临床内科杂志,2020,37
应用价值。 (6):447-448.
参考文献 LIU H J,GENG J,HE Z H,et al. Effect of levosimendan
[ 1 ] 田文龙,程红颖,董士民. 左西孟旦治疗严重脓毒症及脓 on myocardial inhibition and cardiac function in sepsis[J].
毒症休克的临床疗效的 Meta 分析[J]. 临床荟萃,2018, J Clin Intern Med,2020,37(6):447-448.
[13] PAN J,YANG Y M,ZHU J Y,et al. Multiorgan drug
33(7):562-567.
action of levosimendan in critical illnesses[J]. Biomed Res
TIAN W L,CHENG H Y,DONG S M. Meta analysis of
Int,2019,2019:9731467.
levosimendan in treatment of severe sepsis and septic
shock[J]. Clin Focus,2018,33(7):562-567. [14] OSPINA-TASCÓN G A,CALDERÓN-TAPIA L E. Inodi‐
lators in septic shock:should these be used? [J]. Ann
[ 2 ] LIU D H,NING Y L,LEI Y Y,et al. Levosimendan ver‐
Transl Med,2020,8(12):796.
sus dobutamine for sepsis-induced cardiac dysfunction:a
[15] YANG F,ZHAO L N,SUN Y,et al. Levosimendan as a
systematic review and meta-analysis[J]. Sci Rep,2021,11
new force in the treatment of sepsis-induced cardiomyopa‐
(1):20333.
thy:mechanism and clinical application[J]. J Int Med Res,
[ 3 ] EVANS L,RHODES A,ALHAZZANI W,et al. Survi-
ving sepsis campaign:international guidelines for manage‐ 2019,47(5):1817-1828.
[16] ZANGRILLO A,PUTZU A,MONACO F,et al. Levosi‐
ment of sepsis and septic shock 2021[J]. Intensive Care
mendan reduces mortality in patients with severe sepsis
Med,2021,47(11):1181-1247.
and septic shock:a meta-analysis of randomized trials[J].
[ 4 ] SHEN X D,ZHANG H S,ZHANG R,et al. Progress in
J Crit Care,2015,30(5):908-913.
the clinical assessment and treatment of myocardial de‐
[17] GORDON A C,PERKINS G D,SINGER M,et al. Levosi‐
pression in critically ill patient with sepsis[J]. J Inflamm mendan for the prevention of acute organ dysfunction in
Res,2022,15:5483-5490.
sepsis[J]. N Engl J Med,2016,375(17):1638-1648.
[ 5 ] SANGALLI F,BELLANI G,AFFRONTI A,et al. Levosi‐
[18] GUAN Q C,ZHANG C,LI B B,et al. Meta-analysis of
mendan to facilitate weaning from cardiorespiratory sup‐
the efficacy of levosimendan in the treatment of severe
port in critically ill patients:current evidence and future
sepsis complicated with septic cardiomyopathy[J]. Heart
directions[J]. Minerva Anestesiol,2020,86(6):645-651.
Surg Forum,2023,26(5):E609-E620.
[ 6 ] FARMAKIS D,ALVAREZ J,BEN GAL T,et al. Levosi‐ [19] PONIKOWSKI P,VOORS A A,ANKER S D,et al. 2016
mendan beyond inotropy and acute heart failure:evidence
ESC guidelines for the diagnosis and treatment of acute
of pleiotropic effects on the heart and other organs:an ex‐ and chronic heart failure:the task force for the diagnosis
pert panel position paper[J]. Int J Cardiol,2016,222: and treatment of acute and chronic heart failure of the
303-312. European Society of Cardiology (ESC) developed with
[ 7 ] PiCCO监测技术操作管理共识专家组. PiCCO监测技术 the special contribution of the Heart Failure Association
操作管理专家共识[J]. 中华急诊医学杂志,2023,32(6): (HFA)of the ESC[J]. Eur Heart J,2016,37(27):2129-
724-735. 2200.
Expert Group of Expert Consensus on Operation Manage‐ [20] TAN R M,GUO H,YANG Z N,et al. Efficacy and safety
ment of PiCCO Monitoring Technology. Expert consensus of levosimendan in patients with sepsis:a systematic review
on operation management of PiCCO monitoring techno- and network meta-analysis[J]. Front Pharmacol,2024,15:
logy[J]. Chin J Emerg Med,2023,32(6):724-735. 1358735.
[ 8 ] SINGER M,DEUTSCHMAN C S,SEYMOUR C W,et (收稿日期:2024-03-25 修回日期:2024-09-09)
al. The third international consensus definitions for sepsis (编辑:张元媛)
中国药房 2024年第35卷第20期 China Pharmacy 2024 Vol. 35 No. 20 · 2521 ·

